A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...

The company holds several patents for the composition and use of BCG combined with Anktiva in bladder cancer treatment. The ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...

But when cancer develops, it often uses tactics to fool the immune ... In this trial, the RUTI vaccine was administered alongside the standard BCG treatment. The results were promising: RUTI ...

A new systematic review explores how prehabilitation—through exercise, education, nutrition, and lifestyle changes—affects ...

Following surgery to remove the tumor, bladder cancer patients are typically given a live Bacillus Calmette Guerin (BCG) inoculation ... over and above standard treatment, the burden on patients ...

They previously received a median 12 instillations of BCG, and some also received systemic immunotherapy (pembrolizumab). No grade 3 or higher treatment-related adverse events (TRAEs) or deaths ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...